泰恩康(301263.SZ):籌劃第二期員工持股計劃
格隆匯6月20日丨泰恩康(301263.SZ)公佈,結合公司實際情況,公司擬推出第二期員工持股計劃,在符合相關法律法規規定的前提下,本次員工持股計劃的規模不低於人民幣15,000萬元(含本數)且不超過人民幣20,000萬元(含本數),以公司2025年6月20日收盤價33.77元/股作爲股票平均買入價格測算,本次員工持股計劃涉及的股票下限數量約爲444.18萬股,上限數量約爲592.24萬股,不超過公司截至本公告披露日總股本的1.39%。根據《關於上市公司實施員工持股計劃試點的指導意見》,本次員工持股計劃的持股期限不得低於12個月。本次員工持股計劃股票來源爲擬通過二級市場購買(包括大宗交易、競價交易)、通過協議轉讓定向受讓股東股份以及法律法規許可的方式獲得股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.